I have searched the papers to be presented at ASH 2017 and there is no mention of AZD0466. There are mentions however of preclinical and Phase 1 clinical findings for other Astrazeneca drugs (e.g.
Preclinical and Early Phase 1 Clinical Data of AZD2811 Nanoparticle in AML, an Aurora B Kinase Inhibitor).
The general thrust of the papers was, as one might expect, focused on the medical outcomes and while there were some papers on the mechanisms of blood disease there was little about pre-clinical research.
So you were perhaps being a little hard on yourself AB. ASH is not the showcase for preclinical findings, but it is for clinical findings and basic research.
I hereby revoke your one month suspension as being grossly excessive and instead sentence to you to suspension for one day (already served).
